By Counterforce Health Team in Vitrakvi (larotrectinib) —

Getting Vitrakvi (Larotrectinib) Covered by Cigna in New Jersey: Prior Authorization Guide and Appeal Scripts

Answer Box: Getting Vitrakvi (Larotrectinib) Covered by Cigna in New Jersey

Eligibility: Cigna requires prior authorization for Vitrakvi (larotrectinib) with documented NTRK gene fusion, unresectable/metastatic solid tumors, and oncologist prescribing. Fastest path: Submit PA request via CoverMyMeds portal with NTRK fusion test results, prior therapy documentation, and medical necessity letter. First step today: Contact your oncologist to ensure they have your complete molecular pathology report showing NTRK gene fusion and can submit the prior authorization electronically. New Jersey's 60-day grace period protects ongoing treatment during plan transitions, and external appeals through Maximus provide binding review within 7 days for urgent cases.

Table of Contents

  1. Why New Jersey State Rules Matter
  2. Cigna's Prior Authorization Requirements
  3. Step Therapy Protections in New Jersey
  4. Continuity of Care During Transitions
  5. Appeals Process: Internal and External Review
  6. Practical Scripts and Templates
  7. Understanding Plan Limitations
  8. Quick Reference Guide
  9. FAQ

Why New Jersey State Rules Matter

New Jersey's insurance regulations provide crucial protections for patients seeking coverage of specialty oncology drugs like Vitrakvi (larotrectinib). These state laws work alongside your Cigna plan's policies to ensure timely access to medically necessary treatments.

Starting in 2025, New Jersey law A1255 requires insurers to honor existing prior authorizations for 60 days when you switch plans, preventing treatment interruptions during insurance transitions. Additionally, once approved, your prior authorization for chronic conditions like cancer remains valid for 180 days.

The state also mandates specific response times: insurers must decide on coverage within 24 hours for urgent requests and 72 hours for non-urgent requests. For Vitrakvi, which treats rare NTRK fusion-positive cancers, this timeline protection is critical.

Note: These protections apply to fully-insured commercial plans and NJ FamilyCare. Self-funded employer plans follow federal ERISA rules, which may differ.

Cigna's Prior Authorization Requirements

Cigna requires prior authorization for Vitrakvi (larotrectinib) through their specialty pharmacy network, typically Express Scripts or Accredo. Here's what your oncologist must submit:

Coverage Requirements Table

Requirement What It Means Where to Find It Source
NTRK Gene Fusion Test Validated molecular pathology report showing NTRK fusion Lab report with assay method and fusion partner Cigna Precertification Guide
Oncologist Prescriber Board-certified oncologist or specialist Provider directory verification Cigna Provider Directory
Tumor Status Unresectable or metastatic solid tumor Imaging reports, staging documentation FDA Label Requirements
Prior Therapy Documentation Evidence of previous treatments if required by plan Treatment history, response/failure notes Plan-specific policy

Step-by-Step: Fastest Path to Approval

  1. Confirm NTRK Fusion Testing (Patient/Oncologist): Ensure you have a validated molecular pathology report documenting the specific NTRK gene fusion. This is the most critical requirement.
  2. Gather Treatment History (Oncologist): Document any prior cancer therapies, their outcomes, and why Vitrakvi is medically necessary for your specific tumor type.
  3. Submit Electronic PA (Oncologist): Use CoverMyMeds, Surescripts, or Cigna's portal for fastest processing. Alternative: fax to 866-873-8279.
  4. Include Medical Necessity Letter (Oncologist): Detailed clinical rationale addressing FDA indications, tumor characteristics, and treatment goals.
  5. Follow Up Within 72 Hours (Patient/Clinic): Contact Cigna at 800-88CIGNA to confirm receipt and expected timeline.
  6. Request Expedited Review if Urgent (Oncologist): If treatment delay could harm your health, explicitly request expedited processing (24-hour decision).
  7. Prepare for Potential Appeal (Patient): If denied, you have 180 days to appeal internally before pursuing external review.

Step Therapy Protections in New Jersey

New Jersey's step therapy reform, effective January 2026 through Assembly Bill A1825, strengthens patient access to prescribed therapies. For Vitrakvi, this means:

Exception Criteria: Your oncologist can request a step therapy exception if:

  • Standard therapies are contraindicated or likely to cause adverse reactions
  • You've previously tried and failed required medications
  • The preferred drug is not in your best interest based on clinical guidelines

Timeline Protection: Insurers must respond to step therapy exception requests within 24 hours for urgent cases or 72 hours for standard requests.

Documentation Requirements: Your oncologist should include:

  • Clinical rationale for bypassing step therapy
  • Evidence of contraindications or previous failures
  • Citations to oncology guidelines supporting Vitrakvi use

Continuity of Care During Transitions

New Jersey provides robust continuity of care protections during insurance changes:

Grace Period Protections

  • Prior Authorization Grace Period: 60 days for existing approvals when switching plans
  • Provider Network Changes: 90 days of continued in-network coverage if your oncologist leaves Cigna's network during active treatment
  • Prior Authorization Validity: 180 days for chronic condition approvals

How to Activate Protections

  1. Notify Both Insurers: Contact your old and new plans immediately when switching
  2. Request Written Confirmation: Get documentation that your Vitrakvi approval will continue
  3. Submit Transition Forms: Complete any required continuity of care paperwork
  4. Monitor Coverage: Verify that prescriptions continue filling without interruption

Appeals Process: Internal and External Review

If Cigna denies coverage for Vitrakvi, New Jersey's appeal system provides multiple review levels:

Internal Appeals (Cigna)

Stage 1: Informal review with medical director discussion

  • Timeline: 72 hours (urgent), 10 days (standard)
  • Submit to: Cigna member services or provider portal
  • Required: Denial letter, medical records, physician statement

Stage 2: Formal panel review (group plans only)

  • Timeline: 30 days after Stage 1 decision
  • Submit to: Cigna appeals department
  • Required: Complete medical file, updated physician letter

External Review (New Jersey IHCAP)

Administered by Maximus Federal Services, New Jersey's Independent Health Care Appeals Program provides binding external review:

Eligibility: After completing internal appeals for fully-insured plans Timeline: 5 business days for preliminary review, 7 business days for urgent decisions, 45 days for standard cases Cost: Free to patients; insurers pay all fees Submit to: Maximus NJ IHCAP portal or mail Contact: 1-888-393-1062

Appeals Timeline Table

Appeal Level Timeline (Urgent) Timeline (Standard) Decision Binding
Cigna Stage 1 72 hours 10 days No
Cigna Stage 2 72 hours 30 days No
External (IHCAP) 7 days 45 days Yes

Practical Scripts and Templates

Patient Phone Script for Cigna

"Hello, I'm calling about prior authorization for Vitrakvi, generic name larotrectinib, for my NTRK fusion-positive cancer. My oncologist submitted the request [date] via [portal/fax]. Can you confirm receipt and provide the expected decision timeline? If there are any missing documents, please let me know immediately so we can submit them today."

Medical Necessity Letter Checklist for Oncologists

Essential Elements:

  • Patient demographics and diagnosis with ICD-10 codes
  • NTRK gene fusion documentation (assay method, fusion partner)
  • Tumor staging and unresectability/metastatic status
  • Prior therapy history and outcomes
  • Clinical rationale citing FDA labeling and oncology guidelines
  • Dosing plan and monitoring schedule
  • Statement of medical necessity and urgency

Appeal Letter Template

"I am appealing the denial of Vitrakvi (larotrectinib) coverage dated [date], reference number [number]. The denial stated: '[quote exact reason].'

This decision should be reversed because:

  1. My NTRK gene fusion has been confirmed by validated testing (attached report)
  2. My tumor is unresectable/metastatic as documented by imaging
  3. Vitrakvi is FDA-approved for my specific condition regardless of tumor histology
  4. [Additional specific clinical factors]

Per New Jersey regulations N.J.A.C. 11:24-8, I request [expedited/standard] review. All supporting documentation is attached."

Understanding Plan Limitations

ERISA vs. State-Regulated Plans

State-Regulated Plans (fully-insured commercial, NJ FamilyCare):

  • Subject to New Jersey protections described above
  • External review through IHCAP available
  • 60-day grace periods apply

Self-Funded Employer Plans (ERISA):

  • Follow federal rules, not state protections
  • Different appeal timelines and processes
  • External review through federal contractors

Identifying Your Plan Type

Check your insurance card or Summary Plan Description for:

  • "Insured by" language indicates state-regulated
  • "Administered by" typically indicates self-funded
  • When in doubt, call Cigna member services

Quick Reference Guide

Key Contacts

  • Cigna Member Services: 800-88CIGNA (800-882-4462)
  • Cigna Provider Services: 800-882-4462
  • Prior Authorization Fax: 866-873-8279
  • NJ IHCAP Appeals: 1-888-393-1062
  • NJ DOBI Consumer Hotline: 1-800-446-7467

Important Forms and Portals

Key Deadlines

  • Internal Appeals: 180 days from denial
  • External Appeals: 4 months from final internal denial
  • PA Grace Period: 60 days during plan transitions
  • Decision Timelines: 24 hours (urgent), 72 hours (standard)

FAQ

How long does Cigna prior authorization take for Vitrakvi in New Jersey? Standard requests: 72 hours; urgent requests: 24 hours. Electronic submissions through CoverMyMeds or Cigna's portal typically process faster than fax submissions.

What if Vitrakvi is not on Cigna's formulary? Request a formulary exception with clinical documentation showing medical necessity and why formulary alternatives are inappropriate. Include NTRK fusion test results and oncology guidelines supporting tissue-agnostic use.

Can I request an expedited appeal if Cigna denies coverage? Yes, if treatment delay would jeopardize your health. Your oncologist must explicitly state the clinical urgency in the appeal documentation.

Does step therapy apply to Vitrakvi for NTRK fusion-positive tumors? Possibly, depending on your specific plan. However, the tissue-agnostic nature of NTRK fusions often supports step therapy exceptions, especially when standard therapies lack activity against your specific tumor type.

What happens if my oncologist leaves Cigna's network during treatment? Under federal continuity of care rules, you can continue treatment with your oncologist at in-network rates for up to 90 days while transitioning to a new provider.

How much does Vitrakvi cost, and are there assistance programs? The wholesale cost is approximately $32,800 per month. Bayer offers TRAK Assist, including a $0 copay program for eligible commercial patients. Contact 1-888-TRAK-4-U (1-888-872-5248) for assistance.

Counterforce Health helps patients, clinicians, and specialty pharmacies get prescription drugs approved by turning insurance denials into targeted, evidence-backed appeals. Our platform ingests denial letters, plan policies, and clinical notes, then identifies the denial basis and drafts point-by-point rebuttals aligned to each plan's specific rules. For Vitrakvi appeals, we pull the right citations from FDA labeling, peer-reviewed studies, and specialty oncology guidelines, weaving them into appeals with required clinical facts like NTRK fusion documentation and prior therapy history. Visit CounterforceHealth.org to learn how we can help streamline your prior authorization and appeals process.

When navigating Cigna's prior authorization requirements for Vitrakvi in New Jersey, having the right documentation and understanding state protections can make the difference between approval and denial. If you encounter roadblocks, remember that Counterforce Health specializes in turning denials into successful appeals by crafting evidence-backed responses tailored to each payer's specific criteria.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. Insurance policies and state regulations may change; verify current requirements with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.